Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis

被引：0

作者：

Conaghan, Philip G. ^{[1
]}

DiFrancesco, Anita ^{[2
]}

Swearingen, Christopher J. ^{[2
]}

Kennedy, Sarah ^{[2
]}

Simsek, Ismail ^{[2
]}

Tambiah, Jeymi ^{[2
]}

Yazici, Yusuf ^{[2
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[2] Samumed LLC, San Diego, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1201

引用

页数：2

共 50 条

[21] RADIOGRAPHIC OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: WEEK 26 INTERIM ANALYSIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Skrepnik, N.
Armas, E.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M. C.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 121 - 121
[22] JOINT SPACE WIDTH CRITERIA CAN REDUCE KNEE OA TRIAL HETEROGENEITY: PHASE 2 POST-HOC DATA FROM WNT PATHWAY INHIBITOR, SM04690
Conaghan, P.
Tambiah, J.
Swearingen, C.
Kennedy, S.
Bowes, M.
Brett, A.
Latterman, C.
OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S53 - S54
[23] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (SM04690), A WNT PATHWAY MODULATOR, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Tambiah, J.
Kennedy, S.
Swearingen, C.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S45 - S46
[24] TREATMENT OF KNEE OSTEOARTHRITIS WITH SM04690 IMPROVED WOMAC A1 'PAIN ON WALKING' RESULTS FROM A 52 WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, WNT PATHWAY INHIBITOR
Kennedy, S.
Ghandehari, H.
Swearingen, C.
Tambiah, J.
Hochberg, M.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 81 - 82
[25] JOINT SPACE WIDTH INCLUSION CRITERIA CAN REDUCE KNEE OSTEOARTHRITIS TRIAL HETEROGENEITY: POST-HOC DATA FROM A PHASE 2 TRIAL OF WNT PATHWAY INHIBITOR, SM04690
Conaghan, P.
Tambiah, J.
Swearingen, C. J.
Kennedy, S.
Bowes, M.
Brett, A.
Lattermann, C.
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S274 - S275
[26] Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 "Pain on Walking" - Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
Tambiah, Jeyanesh
Kennedy, Sarah
Ghandehari, Heli
Swearingen, Christopher
Hochberg, Marc C.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[27] DISCOVERY OF A SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04690) AS A POTENTIAL DISEASE MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS
Hood, J. D.
Deshmukh, V.
Barroga, C.
Hu, Y.
OSTEOARTHRITIS AND CARTILAGE, 2016, 24 : S14 - S15
[28] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK/DYRK INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGEPROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POSTTRAUMATIC OA
Seo, T.
Deshmukh, V.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S297 - S298
[29] DISCOVERY OF A SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04690) AS A POTENTIAL DISEASE MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS
Hood, J.
Barroga, C.
Hu, Y.
Deshmukh, V.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 81 - 81
[30] DISCOVERY OF A SMALL MOLECULE WNT PATHWAY INHIBITOR (SM04690) AS A POTENTIAL DISEASE MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS
Lane, N. E.
Deshmukh, V.
Barroga, C.
Hu, H.
Kc, S.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S56 - S57

← 1 2 3 4 5 →